Llc Todua Clinic

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Lung cancer8 trials
• Ulcerative colitis2 trials
• Bladder cancer1 trial
• Colorectal cancer1 trial
• Deep vein thrombosis and pulmonary embolism1 trial
• Gastric and oesophageal cancer1 trial
• Graves' disease1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 310 trials
• Phase 25 trials
• Phase 2/31 trial

Status

• Active, not recruiting7 trials
• Recruiting6 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• Amgen3 trials
• Regeneron Pharmaceuticals3 trials
• BioNTech SE2 trials
• Pfizer2 trials
• argenx1 trial
• and 5 more

Running trials

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· SystImmune Inc.· Source

  Contact: Tamar Melkadze (principal investigator)

• Recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

  NCT07570316· Phase 3· argenx· Source

  Contact: Tamar Khutsishvili, MD

• Recruiting

  REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

  NCT07410117· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Recruiting

  A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

  NCT06532006· Phase 3· Shanghai Henlius Biotech· Source

  Contact: Ying Li

• Active, not recruiting

  Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

  NCT06430866· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· Phase 3· Amgen· Source

• Active, not recruiting

  A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

  NCT06054555· Phase 3· Amgen· Source

• Active, not recruiting

  A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

  NCT05557591· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

  NCT05816252· Phase 2· Klus Pharma Inc.· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Graves' disease1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

  NCT06331299· Phase 3· UroGen Pharma Ltd.· Source

• Terminated

  A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

  NCT05256381· Phase 2· SOTIO Biotech AG· Source

• Completed

  Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

  NCT04607837· Phase 2· Pfizer· Source